Orthocell Secures First Orders for Nerve Repair Device in Singapore; Shares Up 5%

MT Newswires Live

2024/12/12

Orthocell (ASX:OCC) received the first orders for its peripheral nerve repair device Remplir in Singapore as it advanced its commercialization activities in the market, according to a Thursday filing with the Australian bourse.

The product is set for launch in the first quarter of 2025 via distributor Device Technologies Asia, which also handles the distribution of Remplir in Australia and New Zealand, the filing said.

The company's shares were up almost 5% in recent Thursday trade.

Price (AUD): $1.05, Change: $+0.05, Percent Change: +4.50%

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2490810271"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2490810271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2490810271?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-12 08:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490810271","market":"hk","top_or_hot":-1,"title":"Orthocell Secures First Orders for Nerve Repair Device in Singapore; Shares Up 5%","media":"MT Newswires Live","content":"<html><body><p> Orthocell (ASX:OCC) received the first orders for its peripheral nerve repair device Remplir in Singapore as it advanced its commercialization activities in the market, according to a Thursday filing with the Australian bourse.</p><p>The product is set for launch in the first quarter of 2025 via distributor Device Technologies Asia, which also handles the distribution of Remplir in Australia and New Zealand, the filing said.</p><p>The company's shares were up almost 5% in recent Thursday trade.</p><p>Price (AUD): $1.05, Change: $+0.05, Percent Change: +4.50%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orthocell Secures First Orders for Nerve Repair Device in Singapore; Shares Up 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrthocell Secures First Orders for Nerve Repair Device in Singapore; Shares Up 5%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-12-12 08:27</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Orthocell (ASX:OCC) received the first orders for its peripheral nerve repair device Remplir in Singapore as it advanced its commercialization activities in the market, according to a Thursday filing with the Australian bourse.</p><p>The product is set for launch in the first quarter of 2025 via distributor Device Technologies Asia, which also handles the distribution of Remplir in Australia and New Zealand, the filing said.</p><p>The company's shares were up almost 5% in recent Thursday trade.</p><p>Price (AUD): $1.05, Change: $+0.05, Percent Change: +4.50%</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0426412945.USD","symbol_name":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490810271","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490810271","pubTimestamp":1733963272,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Orthocell  received the first orders for its peripheral nerve repair device Remplir in Singapore as it advanced its commercialization activities in the market, according to a Thursday filing with the Australian bourse.The product is set for launch in the first quarter of 2025 via distributor Device Technologies Asia, which also handles the distribution of Remplir in Australia and New Zealand, the filing said.The company's shares were up almost 5% in recent Thursday trade.Price : $1.05, Change: $+0.05, Percent Change: +4.50%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0426412945.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) ACC","LU0426417589.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","LU1043141123.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) INC 2","OCC.AU":"ORTHOCELL LTD","XJO.AU":"标普/澳交所 200指数","XKO.AU":"标普/澳交所 300指数","LU2238339852.HKD":"NINETY ONE GSF GLOBAL ENVIRONMENT \"A\" (HKD) ACC","BK7508":"医药生物股","LU0994945656.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC 2","BK7067":"生物科技","XAO.AU":"标普/澳交所 普通股指数","BK4125":"广播"},"translate_title":"Orthocell在新加坡获得第一批神经修复设备订单；股价上涨5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCC.AU":0.9,"XAO.AU":0.9,"AUD":1,"XJO.AU":0.9,"XKO.AU":0.9},"content_text":"Orthocell (ASX:OCC) received the first orders for its peripheral nerve repair device Remplir in Singapore as it advanced its commercialization activities in the market, according to a Thursday filing with the Australian bourse.The product is set for launch in the first quarter of 2025 via distributor Device Technologies Asia, which also handles the distribution of Remplir in Australia and New Zealand, the filing said.The company's shares were up almost 5% in recent Thursday trade.Price (AUD): $1.05, Change: $+0.05, Percent Change: +4.50%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}